Blood clot patient treated with heparin alternative – About Your Online Magazine

The patient received the Johnson & Johnson (Janssen) vaccine elsewhere and was later admitted to the UCHealth emergency department.

AURORA, Colo – Patient admitted to the University Hospital Emergency Department (UCHealth) with blood clots developed from the Johnson and Johnson (Janssen) vaccine, was treated with an alternative anticoagulant, for Guidance from Centers for Disease Control and Prevention (CDC), according to the hospital.

> The video above is from a CDC conference where a US health panel recommends restarting J&J COVID-19 vaccinations.

On April 13, the day the CDC stopped the Johnson and Johnson vaccine, a patient was brought to UCHealth suffering from vaccine-induced thrombocytopenia (VITT), the hospital said.

The patient, a woman in her 40s, went to the emergency room 12 days after receiving the Johnson and Johnson vaccine, according to the hospital.

The CDC warned that these blood clots, which may occur from a rare complication of the Johnson and Johnson vaccine, should not be treated with the usual first-line drug, heparin, which can worsen clots, UCHealth said in a release. .

The CDC did not specify which alternative should be used in these cases, said UCHealth. Doctors at the University of Colorado School of Medicine worked quickly to recognize the condition and treat the patient with an alternative anticoagulant, bivalirudin, the hospital said.

“Our experience shows us that these clot reactions are very rare and can be treated,” said R. Todd Clark, MD, MBA, lead co-author and assistant professor of emergency medicine at the University of Colorado School of Medicine. “People can feel comfortable being vaccinated with any of the authorized vaccines, including the J&J vaccine. Being vaccinated is a critical step in combating this pandemic so that we can return to our normal lives. “

“The single-dose vaccination option will be convenient for providing patients in our emergency departments who may not have received the vaccine yet due to various barriers,” said Dr. Richard Zane, director of innovation and professor and chief of medicine at UCHealth emergency at the University of Colorado School of Medicine. “Although the risk of developing blood clots is extremely rare, we know that this condition can be treated safely. In the very unlikely event that a patient develops VITT, they will be in good hands with a team that can treat it.”

This was the first known case of a VITT patient treated with a heparin alternative, following CDC guidelines, according to the hospital.

RELATED: From 139,000 shots of J&J, three reports of clots in Colorado

RELATED: Colorado recommends immediately restarting the J&J vaccine, some providers choose to go slow


Paula Fonseca